Homologous recombination repair deficient prostate cancer represents an immunologically distinct subtype. - van Wilpe S; Simnica D; Slootbeek P; van Ee T; Pamidimarri Naga S; Gorris MAJ; van der Woude LL; Sultan S; Koornstra RHT; van Oort IM; Gerritsen WR; Kroeze LI; et al. (Oncoimmunology, 2022)